The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation

Peng Liu; Liwei Zhao; Laurence Zitvogel; Oliver Kepp; Guido Guido Kroemer

doi:10.1038/s41418-023-01232-y

Related publications

Article2024

BCL2 inhibition stimulates dendritic cell function for improved anticancer immunotherapy

Peng Liu, Liwei Zhao, Guido Guido Kroemer, Oliver Kepp

Article2014

Trial watch: Dendritic cell-based anticancer therapy

Norma Bloy, Jonathan Pol, Fernando Aranda, Alexander Eggermont, Isabelle Cremer, Wolf H. Fridman, Jitka Fučíková, Jérôme Galon, Éric Tartour, Radek Špíšek, Madhav V. Dhodapkar, Laurence Zitvogel, Guido Guido Kroemer, Lorenzo Galluzzi

Article2017

Trial watch: Dendritic cell-based anticancer immunotherapy

Abhishek D. Garg, Mónica Vara‐Pérez, Marco B.E. Schaaf, Patrizia Agostinis, Laurence Zitvogel, Guido Guido Kroemer, Lorenzo Galluzzi

Article2019

Intestinal dysbiosis mediates experimental autoimmune pancreatitis via activation of plasmacytoid dendritic cells

Ken Kamata, Tomohiro Watanabe, Kosuke Minaga, Akane Hara, Tomoe Yoshikawa, Ayana Okamoto, Kentaro Yamao, Mamoru Takenaka, Ah-Mee Park, Masatoshi Kudo

Article2023

BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance

Liwei Zhao, Peng Liu, Misha Mao, Shuai Zhang, Camille Bigenwald, Charles‐Antoine Dutertre, Christian H.K. Lehmann, Hui Pan, Nicolas Paulhan, Lukas Amon, Aitziber Buqué, Takahiro Yamazaki, Lorenzo Galluzzi, Benoit Kloeckner, Aymeric Silvin, Yuhong Pan, Hui Chen, Ai-Ling Tian, Pierre Ly, Diana Dudziak, Laurence Zitvogel, Oliver Kepp, Guido Guido Kroemer